Research Progress on the Cardiotoxicity of EGFR-TKIs in Non-Small Cell Lung Cancer

Area of Science:

• Oncology
• Cardiology
• Pharmacology

Background:

• Targeted therapy, particularly for non-small cell lung cancer (NSCLC), has advanced significantly with molecular biology techniques.
• Epidermal growth factor receptor (EGFR) inhibitors represent a key targeted therapy, with three generations offering distinct clinical benefits.
• Emerging preclinical data highlight significant cardiovascular complications associated with EGFR-tyrosine kinase inhibitors (EGFR-TKIs), including heart failure and QT prolongation.

Purpose of the Study:

• To review the potential cardiotoxicity associated with third-generation EGFR-TKIs used in NSCLC treatment.
• To elucidate the mechanisms underlying EGFR-TKI-induced cardiotoxicity.
• To provide guidance for early identification, prevention, and management of cardiotoxicity in NSCLC patients undergoing targeted therapy.

Main Methods:

• Literature review of preclinical and clinical studies on EGFR-TKIs and cardiotoxicity.
• Analysis of reported cardiovascular adverse events in NSCLC patients treated with third-generation EGFR-TKIs.
• Synthesis of mechanistic insights into EGFR-TKI-mediated cardiac damage.

Main Results:

• Cardiotoxicity is a significant concern with EGFR-TKIs, impacting NSCLC treatment efficacy and patient survival.
• Third-generation EGFR-TKIs present unique cardiotoxic profiles that require careful monitoring.
• Mechanisms of cardiotoxicity involve various pathways affecting cardiac function and structure.

Conclusions:

• Cardiotoxicity is a critical factor in NSCLC management, becoming the second leading cause of death.
• Clinicians must be vigilant in recognizing and managing cardiovascular risks associated with third-generation EGFR-TKIs.
• Proactive strategies are essential to mitigate cardiotoxicity and optimize therapeutic outcomes for NSCLC patients.